Meridian Bioscience Reports Fourth Quarter and Full-Year Fiscal 2019 Operating Results and Provides Fiscal 2020 Guidance
CINCINNATI, Nov. 07, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2019. Fourth Quarter 2019 Highlights (Comparison to Fourth Quarter Fiscal 2018): Consolidated revenue decreased 4% to $50.8 million (3% decrease in constant-currency) Diagnostics segment revenues decreased 9% to $33.4 […]
Meridian submits Curian™ analyzer and the Curian™ HpSA assay to the FDA
CINCINNATI, Nov. 06, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has submitted Curian™ and the Curian™ HpSA assay to the FDA for review. This platform and assay are designed to specifically detect Helicobacter pylori antigens in human stool using fluorescent lateral flow technology. Curian™ HpSA is intended to aid in […]
Meridian Bioscience to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on November 7, 2019
CINCINNATI, Oct. 16, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report fourth quarter and full year 2019 financial results Thursday, November 7, 2019. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a […]
Meridian Bioscience Reports Third Quarter 2019 Operating Results
CINCINNATI, Ohio, July 30, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter and first nine months ended June 30, 2019. Third Quarter 2019 Highlights (Comparison to Third Quarter Fiscal 2018): Consolidated revenue decreased 6% to $48.4 million (5% decrease in constant-currency) Diagnostics segment revenues decreased 9% […]
Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019
CINCINNATI, July 10, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019 financial results Tuesday, July 30, 2019. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Interim Chief Financial Officer and Chief Accounting Officer, will host a conference call […]
Meridian Bioscience Announces Closing of Transaction to Acquire Business of GenePOC
CINCINNATI, June 03, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has completed its previously announced acquisition of the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays. About Meridian Bioscience, Inc. […]
Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition
CINCINNATI, April 30, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter and first six months ended March 31, 2019. Second Quarter 2019 Highlights: Total revenue decreased 11% to $50.2 million, as compared to $56.5 million in the second quarter of fiscal 2018 (10% decrease in constant-currency) […]
Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform
CINCINNATI, April 30, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays. Founded in 2007, […]
Meridian Launches a New Inhibitor Tolerant qPCR Reagent to Significantly Simplify Molecular Diagnostic Workflows From Crude Samples
CINCINNATI, April 18, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate workflows and improve DNA target amplification and quantification from crude samples; adding to its growing portfolio of molecular diagnostic products. A variety of different inhibitors inherent to clinical and […]
Meridian Bioscience to Hold Second Quarter 2019 Financial Results Conference Call on April 30, 2019
CINCINNATI, April 10, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report second quarter 2019 financial results Tuesday, April 30, 2019. Jack Kenny, Chief Executive Officer, and Eric Rasmussen, Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern […]